The paradox of the PSA test. (MIT Press)
Serving to patients with cancer feel extra indulge in anyone who issues and much less indulge in a amount. (Time)
Deciphera Prescribed medications introduced that the switch-take care of an eye on tyrosine kinase inhibitor ripretinib (Qinlock) failed to make stronger progression-free survival versus sunitinib (Sutent) in a phase III trial of previously handled gastrointestinal stromal tumors.
Patients with developed cancers ineligible for scientific trials in most cases acquired immunotherapy despite lack of evidence that the treatment would possibly per chance possibly well be precious. (Penn Pills, JAMA Oncology)
Undoubtedly one of the fundamental very most exciting research of its kind confirmed the affiliation between use of immune checkpoint inhibitors and myocarditis and characterised the forms of coronary heart points that happen. (Circulation, University of California San Francisco)
Moderate survival for 2 of the three main forms of developed breast cancer has doubled all the plan thru the final decade. (Evolved Breast Cancer Global Alliance)
Neoadjuvant treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) vastly improved tournament-free survival in resectable non-runt cell lung cancer, Bristol Myers Squibb introduced.
Artificial intelligence (AI)-assisted skin cancer prognosis is mild no longer willing to be used in routine scientific follow, in phase on account of an absence of photos of skin of coloration weak to put together AI techniques. (National Cancer Research Institute, Lancet Digital Neatly being)
Poet Maggie Smith talks about journal writing as a technique to address loss and uncertainty. (CNN)
Early dispute after nonreconstructive breast cancer surgery also can merely make stronger arm and shoulder feature and cleave wretchedness. (The BMJ)
Probably fresh clues to reduction early prognosis of pancreatic cancer. (National Cancer Research Institute)
Final Up thus far November 11, 2021
-
Charles Bankhead is senior editor for oncology and additionally covers urology, dermatology, and ophthalmology. He joined MedPage As of late in 2007. Note
